KRAS and lung cancer: In this regard, [89Zr]-anti-PD-1 (immuno-PET) may probably perform similarly well in other lung cancer subtypes for which immunotherapy has been approved in frontline treatment or as subsequent lines (KRAS or BRAF mutant lung tumors).